What is HC Wainwright’s Estimate for MDGL FY2024 Earnings?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Stock analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of Madrigal Pharmaceuticals in a research report issued to clients and investors on Tuesday, January 14th. HC Wainwright analyst E. Arce forecasts that the biopharmaceutical company will post earnings of ($22.53) per share for the year. HC Wainwright has a “Buy” rating and a $400.00 price target on the stock. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($23.77) per share. HC Wainwright also issued estimates for Madrigal Pharmaceuticals’ Q4 2024 earnings at ($3.31) EPS, Q1 2025 earnings at ($2.10) EPS, Q2 2025 earnings at ($0.73) EPS, Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at $0.24 EPS, FY2025 earnings at ($2.97) EPS, FY2026 earnings at $10.90 EPS, FY2027 earnings at $40.59 EPS, FY2028 earnings at $63.10 EPS and FY2029 earnings at $100.77 EPS.

Several other equities analysts have also recently weighed in on the company. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Madrigal Pharmaceuticals in a report on Wednesday, November 20th. StockNews.com raised Madrigal Pharmaceuticals to a “sell” rating in a research note on Saturday, October 12th. JMP Securities reiterated a “market outperform” rating and set a $427.00 price objective on shares of Madrigal Pharmaceuticals in a research note on Friday, January 10th. UBS Group raised their target price on shares of Madrigal Pharmaceuticals from $411.00 to $441.00 and gave the company a “buy” rating in a report on Friday, November 1st. Finally, B. Riley upped their price target on shares of Madrigal Pharmaceuticals from $194.00 to $236.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $351.67.

Madrigal Pharmaceuticals Stock Down 0.6 %

Shares of MDGL opened at $272.79 on Friday. The company has a quick ratio of 5.93, a current ratio of 5.98 and a debt-to-equity ratio of 0.15. The firm’s 50 day moving average is $315.33 and its 200-day moving average is $272.58. Madrigal Pharmaceuticals has a 12 month low of $168.25 and a 12 month high of $368.29.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($4.92) earnings per share for the quarter, topping the consensus estimate of ($6.94) by $2.02. The business had revenue of $62.18 million during the quarter, compared to analyst estimates of $34.60 million. During the same quarter last year, the firm earned ($5.34) EPS.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Oppenheimer Asset Management Inc. lifted its stake in Madrigal Pharmaceuticals by 2.1% in the third quarter. Oppenheimer Asset Management Inc. now owns 1,507 shares of the biopharmaceutical company’s stock valued at $320,000 after buying an additional 31 shares during the period. Victory Capital Management Inc. increased its stake in shares of Madrigal Pharmaceuticals by 1.8% in the 3rd quarter. Victory Capital Management Inc. now owns 2,292 shares of the biopharmaceutical company’s stock valued at $486,000 after acquiring an additional 40 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Madrigal Pharmaceuticals by 47.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 211 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 68 shares during the period. Creative Planning boosted its stake in Madrigal Pharmaceuticals by 2.7% during the third quarter. Creative Planning now owns 3,299 shares of the biopharmaceutical company’s stock worth $700,000 after acquiring an additional 87 shares in the last quarter. Finally, Verity Asset Management Inc. boosted its stake in Madrigal Pharmaceuticals by 7.4% during the third quarter. Verity Asset Management Inc. now owns 1,466 shares of the biopharmaceutical company’s stock worth $311,000 after acquiring an additional 101 shares in the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

Insider Activity

In other news, Director Fred B. Craves sold 3,600 shares of the company’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $315.31, for a total value of $1,135,116.00. Following the completion of the transaction, the director now owns 11,000 shares of the company’s stock, valued at $3,468,410. This represents a 24.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Richard S. Levy sold 5,000 shares of the firm’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $300.94, for a total transaction of $1,504,700.00. Following the transaction, the director now directly owns 11,012 shares of the company’s stock, valued at $3,313,951.28. The trade was a 31.23 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 12,000 shares of company stock worth $3,830,836. Insiders own 22.80% of the company’s stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.